Media Pack
News

Current Edition

Volume 16 Issue 2
 
Regional News

China’s new NRDL; Biocon-Viatris biosimilar merger?; Avistone’s $200M series A

China unveiled new inclusions in its national reimbursement drug list, featuring novel therapies from Biogen, Pfizer, Eli Lilly and more. Partners Biocon and Viatris ...
13 December 2021 Regional News antibody drugs | ASLAN Pharmaceuticals
Continue Reading →
Regional News

Merck’s Hilleman Laboratories tees up $58M investment at new Singapore vaccine hub

Singapore has attracted a slate of vaccine heavyweights in recent years. Now, a Merck joint venture is getting in on the action, following in the footsteps of compani...
8 December 2021 Regional News biologics | coronavirus
Continue Reading →
Regional News

GlaxoSmithKline and Vir’s sotrovimab stands up to omicron despite other COVID antibodies falling short

Amid reports that COVID-19 antibody treatments from Regeneron and Eli Lilly lose their effectiveness against the omicron variant, GlaxoSmithKline and Vir Biotechnolog...
8 December 2021 Regional News antibodies | Celltrion
Continue Reading →
Regional News

Pfizer boosts Paxlovid manufacturing capacity as Merck’s rival COVID pill hits surprise efficacy setback

The efficacy data for Pfizer’s oral COVID-19 drug now look so appealing that the Big Pharma company is boosting manufacturing capacity even before an expected emergen...
1 December 2021 Regional News Albert Bourla | antivirals
Continue Reading →
Regional News

Moderna, Regeneron warn about the effectiveness of COVID-19 drugs, vaccines against the omicron variant

As the world assesses the threat posed by the COVID-19 omicron variant, two top companies producing pandemic drugs and vaccines have warned that their current offerin...
1 December 2021 Regional News BioNTech | COVID-19
Continue Reading →
Regional News

Aspen closes in on Africa license for Johnson & Johnson’s COVID-19 vaccine

One of Johnson & Johnson’s long-held pandemic manufacturing partners just made headway in its quest to license the company’s shot in Africa. Aspen Pharmacare on ...
1 December 2021 Regional News Africa | Aspen Pharmacare
Continue Reading →
Regional News

AstraZeneca CEO questions mRNA vaccine superiority, raising theory that his company’s shot offers longer-lasting protection

AstraZeneca’s chief executive Pascal Soriot is challenging the notion that his company's vaccine is inferior to the mRNA vaccines from Moderna and Pfizer. In fact, h...
24 November 2021 Regional News AstraZeneca | BioNTech
Continue Reading →
Regional News

Pfizer to become $100B behemoth next year thanks to COVID-19 drug and vaccine

The COVID-19 pandemic is creating a $100 billion pharma goliath. Pfizer’s revenue could reach $101.3 billion in 2022, with major contributions coming from the compan...
24 November 2021 Regional News antiviral | BioNTech
Continue Reading →
Regional News

Pfizer, like Merck, inks deal to license COVID-19 pill and boost global supply

With its highly anticipated COVID-19 oral treatment seemingly on a fast track to approval, Pfizer already is lining it up to be manufactured as a generic by countries...
17 November 2021 Regional News COVID-19 | COVID-19 pill
Continue Reading →
Regional News

With Merck’s oral COVID-19 med molnupiravir set for authorization, U.S. spends another $1B for 1.4 million courses

With molnupiravir, Merck & Co. and Ridgeback’s oral treatment for COVID-19, apparently on the doorstep of authorization, the U.S. has moved to secure additional d...
10 November 2021 Regional News COVID-19 | FDA
Continue Reading →
 

jcs-white.png

Journal for Clinical Studies

Journal For Clinical Studies has a distinguished editorial advisory board providing the best guidelines for global clinical trials. Your resource for Multisite Studies and emerging markets.

Facebook Linkedin
Journal For Clinical Studies © 2024, All Rights Reserved – Powered by Teksyte